US company says antibody drugs cuts hospitalisation among moderate Covid-19 patients

  • 📰 The Straits Times
  • ⏱ Reading Time:
  • 20 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 63%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

INDIANAPOLIS, INDIANA (REUTERS) - American pharmaceutical company, Eli Lilly and Co said on Wednesday (Sept 16) interim trial data showed its experimental antibody treatment reduced the need for hospitalisation and emergency room visits for patients with moderate Covid-19.. Read more at straitstimes.com.

INDIANAPOLIS, INDIANA - American pharmaceutical company, Eli Lilly and Co said on Wednesday interim trial data showed its experimental antibody treatment reduced the need for hospitalisation and emergency room visits for patients with moderate Covid-19.

Analysts expect antibody treatments could help some patients, as broad distribution of coronavirus vaccine candidates is expected to be lengthy. Of the total 302 patients treated with three different doses of LY-CoV555, five of them, or 1.7 per cent, had to be admitted to a hospital or visited a hospital emergency room, compared with 6 per cent, or 9 out of 150 on placebo, Lilly said.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 8. in İD

Indonesia Berita Terbaru, Indonesia Berita utama